These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 9113039)
1. Intravenous immunoglobulin for multiple sclerosis. Poser CM Lancet; 1997 Apr; 349(9059):1177-8. PubMed ID: 9113039 [No Abstract] [Full Text] [Related]
2. Intravenous immunoglobulin treatment in multiple sclerosis. Gadoth N; Melamed E; Miller A; Steiner I; Abramsky O Neurology; 1999 Jan; 52(1):214-5. PubMed ID: 9921886 [No Abstract] [Full Text] [Related]
3. Intravenous immunoglobulin treatment in multiple sclerosis. Francis G Neurology; 1999 Jan; 52(1):214. PubMed ID: 9921885 [No Abstract] [Full Text] [Related]
4. [Intravenous immunoglobulins (IVIg) in the treatment of multiple sclerosis]. Achiron A; Miron S Ann Med Interne (Paris); 2000 May; 151 Suppl 1():1S41-4. PubMed ID: 10896988 [TBL] [Abstract][Full Text] [Related]
5. Intravenous immunoglobulin, plasmalymphocytapheresis and azathioprine in chronic progressive multiple sclerosis. Uccelli A; Capello E; Fenoglio D; Incagliato M; Valbonesi M; Mancardi GL Ital J Neurol Sci; 1994 Feb; 15(1):51-3. PubMed ID: 8206747 [TBL] [Abstract][Full Text] [Related]
6. [Treatment of multiple sclerosis: current opinion]. Yamamura T No To Shinkei; 2001 Aug; 53(8):707-13. PubMed ID: 11577411 [No Abstract] [Full Text] [Related]
7. [Multiple sclerosis]. Itoyama Y No To Shinkei; 2000 Dec; 52(12):1051-5. PubMed ID: 11193536 [No Abstract] [Full Text] [Related]
8. Intravenous immunoglobulins in MS: a panacea lacking approval? Hohlfeld R Int MS J; 2005 Apr; 12(1):1-2. PubMed ID: 15955271 [No Abstract] [Full Text] [Related]
9. Interferon Beta-1a and intravenous immunoglobulin treatment for multiple sclerosis in Iran. Kalanie H; Gharagozli K; Hemmatie A; Ghorbanie M; Kalanie AR Eur Neurol; 2004; 52(4):202-6. PubMed ID: 15539773 [TBL] [Abstract][Full Text] [Related]
11. Intravenous immunoglobulin treatment in multiple sclerosis. Achiron A; Cohen IR; Lider O; Melamed E Isr J Med Sci; 1995 Jan; 31(1):7-9. PubMed ID: 7836053 [No Abstract] [Full Text] [Related]
12. How should we proceed with disease-modifying treatments for multiple sclerosis? Andersson PB; Waubant E; Goodkin DE Lancet; 1997 Mar; 349(9052):586-7. PubMed ID: 9057726 [No Abstract] [Full Text] [Related]
13. The management of pediatric multiple sclerosis. Yeh EA; Weinstock-Guttman B J Child Neurol; 2012 Nov; 27(11):1384-93. PubMed ID: 22914373 [TBL] [Abstract][Full Text] [Related]
14. [Causal therapy of multiple sclerosis]. Pöhlau D; Rieks M; Postert T; Hoffmann V; Przuntek H Dtsch Med Wochenschr; 1996 Nov; 121(45):1407-14. PubMed ID: 8964231 [No Abstract] [Full Text] [Related]
15. New uses for IVIgG immunoglobulin therapies. Wallington T Vox Sang; 2004 Jul; 87 Suppl 2():155-7. PubMed ID: 15209904 [No Abstract] [Full Text] [Related]
16. Multiple sclerosis. Ford H; Nicholas R Clin Evid; 2005 Dec; (14):1637-51. PubMed ID: 16620466 [No Abstract] [Full Text] [Related]
17. New treatments for multiple sclerosis: a clinical perspective. Thompson AJ; Noseworthy JH Curr Opin Neurol; 1996 Jun; 9(3):187-98. PubMed ID: 8839609 [TBL] [Abstract][Full Text] [Related]